A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Jaktinib (Primary)
- Indications Autoimmune disorders; Cancer; Myelofibrosis
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 02 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 02 Aug 2018 Planned primary completion date changed from 1 Nov 2017 to 30 Aug 2018.
- 27 Oct 2017 New trial record